Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2021 · 10-K
Revenue$8.32M$8.32M−18.9% vs Q4 2020 Net Income-$3.85M-$3.85MN/M vs Q4 2020 EPS Diluted-$0.26-$0.26N/M vs Q4 2020 Operating Income-$4,353,996N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,950,633+141.3% Margins · derivedOperating margin-52.3%−35.3 pt vs Q4 2020
Net margin-46.2%−37.6 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 11, 2022 · 70 d after period end